Su Dan, Nie Man, Yue Jun
Department of Gynecology and Obstetrics, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Chengdu, China.
Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu, China.
Ann Transl Med. 2021 Apr;9(8):710. doi: 10.21037/atm-21-583.
The carcinogenic mechanisms underlying serous ovarian cancer are not fully understood.
Whole-exome sequencing and targeted sequencing were performed in ovarian cancer samples to identify novel molecular markers involved in the process of cell malignancy in ovarian cancer. experiments, the oncogenic roles such as cell proliferation, migration and invasion of G199X and V157fs mutations were investigated deeply.
The present study identified the G199X and V157fs point mutations in the tumor protein P53 gene (). The rate of mutation was 59.2% in a cohort of 76 ovarian cancer patients, compared with 9.0% in a cohort of 156 healthy women. Kaplan-Meier analysis showed that patients with a mutation had a lower 5-year overall survival (OS) rate compared with patients harboring wild type . experiments in an ovarian cancer cell line demonstrated that the G199X and V157fs mutants inhibited P53 protein expression, enhanced proliferation, promoted migration and increased invasion.
This study identified two novel markers, G199X and V157fs mutations in . Functional assays indicated that these mutations enhanced the malignant phenotype in ovarian cancer cells. These novel markers will assist in the diagnosis of ovarian tumors and represent potential targets for the treatment of mutant ovarian cancers.
浆液性卵巢癌的致癌机制尚未完全明确。
对卵巢癌样本进行全外显子测序和靶向测序,以鉴定参与卵巢癌细胞恶性转化过程的新型分子标志物。通过实验,深入研究了G199X和V157fs突变在细胞增殖、迁移和侵袭等致癌作用。
本研究在肿瘤蛋白P53基因中鉴定出G199X和V157fs点突变。在76例卵巢癌患者队列中,突变率为59.2%,而在156名健康女性队列中为9.0%。Kaplan-Meier分析显示,与携带野生型P53的患者相比,携带P53突变的患者5年总生存率较低。在卵巢癌细胞系中的实验表明,G199X和V157fs突变体抑制P53蛋白表达,增强增殖,促进迁移并增加侵袭。
本研究鉴定出两个新型标志物,即P53基因中的G199X和V157fs突变。功能分析表明,这些突变增强了卵巢癌细胞的恶性表型。这些新型标志物将有助于卵巢肿瘤的诊断,并代表P53突变型卵巢癌治疗的潜在靶点。